A small preliminary study evaluated a novel targeted inhibitor of the KRAS G12D mutation in patients with advanced or metastatic pancreatic cancer who had received multiple prior lines of treatment. According to the first results, almost 80% of these heavily pretreated patients achieved the so-called disease control, meaning the tumor has shrunk or at least stopped growing. The study was early and had a small number of patients, so these are preliminary data. The drug is aimed at the specific genetic change KRAS G12D, which is among the frequent mutations in pancreatic cancer. The results were presented at a professional event in San Francisco. The authors report that this is the first data on the effectiveness of this particular drug in this patient group. Safety data and long-term effect on survival were not described in detail in the available text.